Peptide Comparison
MOTS-C vs Humanin
Editorial breakdown of mechanism, evidence, decision criteria, and the misconceptions worth calling out.
Data-derived verdict
MOTS-C has stronger documented evidence (Early Clinical + Animal Studies) than Humanin (Preclinical + Animal Studies) while both occupy the mdp class. When clinical-evidence tier is the deciding factor, MOTS-C is the safer pick. Humanin may still fit a specific research framing the higher-evidence option does not cover: cost, dosing convenience, jurisdictional access, or a particular off-label use case.
Evidence at a glance
FDA-approved Phase 3 Phase 2 / approved abroad Anecdotal + animal Preclinical / flagged
Side-by-side
| MOTS-C | Humanin | |
|---|---|---|
| Class | Mitochondrial-derived peptide (MDP); metabolic regulator | Mitochondrial-derived peptide (MDP); cytoprotective |
| Drug class | Metabolic & Weight | Longevity |
| Mechanism | Activates AMPK; regulates methionine-folate cycle; insulin sensitization; exercise mimetic | Binds BAX and IGFBP3; anti-apoptotic; metabolic regulation |
| Route | SC injection | SC (research) |
| Half-life | ~1 hr | Unknown |
| Dosage (research) | 5 mg SC 2x weekly (research starting dose, range up to 10 mg 3x weekly per anecdotal vendor protocols) | Research dosing varies |
| Evidence tier | Early Clinical + Animal Studies | Preclinical + Animal Studies |
| Research depth | 185 indexed | 184 indexed |
| Availability | Research | Research |
| Reported risks | Limited human trials; unknown long-term effects | Very limited human data |
Reported research data only. "Studied for" and "reported in literature" describe published research focus, not clinical recommendation. Most peptides catalogued here are not FDA-approved for human use.
Frequently asked questions
Should I pick MOTS-C or Humanin?
MOTS-C has stronger documented evidence (Early Clinical + Animal Studies) than Humanin (Preclinical + Animal Studies) while both occupy the mdp class. When clinical-evidence tier is the deciding factor, MOTS-C is the safer pick. Humanin may still fit a specific research framing the higher-evidence option does not cover: cost, dosing convenience, jurisdictional access, or a particular off-label use case.
What is the difference between MOTS-C and Humanin?
MOTS-C is classed as Mitochondrial-derived peptide (MDP); metabolic regulator; Humanin is classed as Mitochondrial-derived peptide (MDP); cytoprotective. Reported mechanism: MOTS-C, Activates AMPK; regulates methionine-folate cycle; insulin sensitization; exercise mimetic; Humanin, Binds BAX and IGFBP3; anti-apoptotic; metabolic regulation. Reported half-life: MOTS-C, ~1 hr; Humanin, Unknown. Routes in published studies: MOTS-C, SC injection; Humanin, SC (research).
Which has stronger evidence, MOTS-C or Humanin?
MOTS-C has the stronger evidence base on PeptideHelper.org's five-step evidence scale, which runs from preclinical to FDA-approved. MOTS-C is graded Early Clinical + Animal Studies, with 3 cited sources on its reference page and 185 indexed studies. Humanin is graded Preclinical + Animal Studies, with 19 cited sources on its reference page and 184 indexed studies.
Which is more accessible, MOTS-C or Humanin?
Neither MOTS-C nor Humanin is an FDA-approved drug. Catalog status: MOTS-C, Research; Humanin, Research. FDA's Pharmacy Compounding Advisory Committee voted 7 for, 5 against, 2 abstentions on 23 July 2026 to recommend MOTS-C for the 503A Bulks List; the vote is advisory and changes nothing by itself.
Are MOTS-C and Humanin ever combined?
MOTS-C and Humanin appear together in no stack catalogued on PeptideHelper.org, and the interaction engine raises no flag for the pair.
Open the PeptideHelper.org compare tool to add more compounds to this side-by-side and filter by evidence tier interactively.
Loading interactive view…